Aggressive T-Cell Non-Hodgkin Lymphoma — Trials

Aggressive T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

289 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 62
Recruiting: 32
Ph III recruiting: 3
Growth YoY: —
Industry share: 21%
Top sponsor: City of Hope Medical Center
Termination share: 33%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (47)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06692452	Tazemetostat Plus CHOP in 1L T-cell Lymphoma	withdrawn	Phase 2	0	Eric Jacobsen, MDOTHER	0	Apr 1, 2026	clinicaltrials
NCT06210750	Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	withdrawn	Phase 2	0	National Cancer Institute (NCI)NIH	0	May 17, 2024	clinicaltrials